# Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)

> **NCT00964028** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Acellular Pertussis
- Diphtheria
- Tetanus
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Infanrix™-IPV/Hib

## Key facts

- **NCT ID:** NCT00964028
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-01
- **Primary completion:** 2010-04-12
- **Final completion:** 2010-04-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00964028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00964028, "Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00964028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*